DE LA SOUL-LED "GOOD HEALTH SUMMIT" LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
MWN-AI** Summary
On February 19, 2026, Morehouse College in Atlanta will host the first annual Good Health: Mind, Body & Soul Summit, inspired by the legendary hip-hop trio De La Soul. This event is designed as an invitation-only gathering aimed at promoting health equity for Black men and families, showcasing a blend of cultural, scientific, and community leadership. The Summit has been made possible through the sponsorship of LIXTE Biotechnology Holdings Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing innovative cancer therapies.
The Summit is a manifestation of De La Soul's commitment to wellness and community impact, following the poignant loss of founding member David Jolicoeur (Trugoy the Dove). The group’s song “Good Health” serves as a thematic foundation for the event, emphasizing the importance of health awareness. Posdnuos, a member of De La Soul, expressed the goal of transforming grief into purpose through wellness advocacy. Fellow member Maseo highlighted that the Summit will facilitate conversations surrounding the true meaning of wealth — focusing on health.
Attendees will include health experts, artists, athletes, and advocates who will engage in discussions on diverse topics affecting health such as cancer, mental health, and family wellness. LIXTE’s CEO, Geordan Pursglove, articulated a vision of linking scientific innovations with the communities that need them most, emphasizing their commitment to advancing cancer care through its leading compound, LB-100.
Overall, the Good Health Summit aims to serve as a crucial platform for addressing wellness within Black communities, enhancing awareness and solidarity through dialogue and expertise. For further details, interested parties can visit www.goodhealthsummit.com.
MWN-AI** Analysis
The upcoming "Good Health: Mind, Body & Soul Summit," set for February 19 at Morehouse College, exemplifies a strategic crossroads of culture, health, and innovative biotechnology. Sponsored by LIXTE Biotechnology Holdings, this summit not only honors the legacy of De La Soul but presents several market implications that investors and industry stakeholders should consider.
Firstly, the partnership between De La Soul and LIXTE symbolizes a growing trend where cultural icons engage in social issues, such as health equity, thereby expanding their influence beyond entertainment. This convergence creates potential marketing leverage for LIXTE, providing a unique platform to connect its cancer therapies with community engagement. This could enhance brand loyalty and broaden its consumer base, particularly within underrepresented communities.
For LIXTE, the endorsement from culturally significant figures could catalyze increased visibility for its lead clinical compound, LB-100. As the company positions itself within an emerging field of cancer biology that seeks to improve patient outcomes, the alignment with public health discussions could translate into heightened investor interest, particularly from ESG-focused funds.
Moreover, the focus on diverse health issues—ranging from mental health to chronic diseases—highlights a comprehensive approach to community wellness. Investors may want to observe how this initiative might leverage positive media coverage and community goodwill to drive stock performance and potential partnerships in the healthcare sector.
In conclusion, investors should monitor LIXTE's engagement outcomes from the summit and assess its impact on both public perception and financial performance. Engaging deeply with community needs while driving innovation in healthcare could position LIXTE favorably in the fast-evolving biopharmaceutical market, warranting closer scrutiny from market analysts and investors alike.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Event Sponsored by LIXTE Biotechnology Holdings,
Developer of Breakthrough Cancer Therapies
Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences of De La Soul, the inaugural Good Health: Mind, Body & Soul Summit will take place February 19 at Morehouse College in Atlanta.
This invitation-only event brings together leaders in health, culture, science, and community to advance health equity for Black men and families. It is made possible by the generous sponsorship of LIXTE Biotechnology Holdings Inc (Nasdaq: LIXT), a clinical-stage pharmaceutical company developing breakthrough cancer therapies.
Rooted in the group’s song “Good Health,” written after the passing of founding member David Jolicoeur (Trugoy the Dove), the Summit represents the next chapter in De La Soul’s commitment to truth, wellness, and cultural impact. Developed in collaboration with Blacksmith holdings, the Summit reflects the group’s evolution from musical pioneers to wellness advocates. Together, De La Soul and Blacksmith partnered with leaders in healthcare, culture, and research to bring the Summit to life.
“This Summit is about turning pain into purpose,” said Kelvin Mercer (Posdnuos). “We’ve always used our music to speak life—and Good Health is about making sure our people live long enough to tell their own stories.”
“This isn’t just a conversation—it’s a call,” added Vincent Mason (Maseo). “Good health is real wealth. We’re creating space for Black men, families, and communities to own that truth—together.”
“Good Health aligns science with culture in a way that is both urgent and deeply human,” said Geordan Pursglove, CEO of LIXTE Biotechnology. “Through our first-in-class oncology compound, LB-100, and LIORA, our European research subsidiary, we are committed to advancing cancer care. This Summit is a powerful space to connect that innovation to the communities that need it most.”
The Summit will convene an intimate audience of health experts, artists, entertainers, athletes, researchers, and advocates. Programming will span topics across mind, body, and soul—including cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness—grounded in science and lived experience.
Attendance is by invitation only. For more details, visit www.goodhealthsummit.com.
About De La Soul
De La Soul is the New York–based trio composed of Posdnuos, Trugoy, and Maseo, creators of the groundbreaking 1989 album 3 Feet High and Rising. Known for their inventive sampling, creative lyricism, and foundational influence on jazz rap and alternative hip-hop, the group has earned widespread acclaim, including a Grammy Award for “Feel Good Inc.” with Gorillaz. Their 2015 Kickstarter-funded album and the Anonymous Nobody… topped the Rap Albums chart and earned a Grammy nomination for Best Rap Album.
For more information and updates on De La Soul, visit:
Website
Facebook
Twitter
BlueSky
Instagram
TikTok
About Blacksmith Holdings
Blacksmith Holdings is a 360° entertainment company founded by Corey Smyth, focused on building culturally driven platforms that connect art, community, and purpose. With a legacy that includes guiding the careers of Dave Chappelle, Vince Staples, Mos Def, and Talib Kweli. Blacksmith continues to champion initiatives that advance wellness, equity, and long-term impact. Additional information about Blacksmith can be found at www.blacksmithnyc.com
About LIXTE Biotechnology Holdings Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at www.lixte.com.
Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.
For more information about LIXTE, contact:
info@lixte.com
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962
FAQ**
How does LIXTE Biotechnology Holdings Inc. plan to leverage its sponsorship of the Good Health Summit to enhance awareness and interest in its clinical initiatives related to its lead compound, particularly in the context of Lixte Biotechnology Holdings Inc. Warrants LIXTW?
In what ways does LIXTE Biotechnology Holdings envision the partnership with De La Soul and Blacksmith Holdings contributing to the broader mission of health equity for Black communities, especially relating to discussions on cancer therapies and Lixte Biotechnology Holdings Inc. Warrants LIXTW?
Can LIXTE Biotechnology Holdings provide insights into how the innovations presented at the Summit will align with its ongoing clinical trials and developing technologies, such as those associated with Lixte Biotechnology Holdings Inc. Warrants LIXTW?
What opportunities for collaboration might arise from the Good Health Summit that could influence LIXTE Biotechnology Holdings’ strategy in advancing cancer treatment, particularly considering the potential impact of Lixte Biotechnology Holdings Inc. Warrants LIXTW?
**MWN-AI FAQ is based on asking OpenAI questions about Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT).
NASDAQ: LIXT
LIXT Trading
7.45% G/L:
$2.74 Last:
7,185 Volume:
$2.75 Open:
